Are Vaccines Fueling New Covid Variants?

The virus appears to be evolving in ways that evade immunity.

A recent article published in the Wall Street Journal suggested that the Covid outbreak heavily affected most vaccinated people. More and more research points to the possibility that repeated vaccinations make people more vulnerable to XBB and contribute to the rapid evolution of the virus.

It can be recalled that the Centers for Disease Control and Prevention (Useless CDC) announced it is monitoring a new COVID-19 variant known as “XBB,” which is responsible for all new infections in the United States.

Back in October, health officials in the US said they were tracking a new Covid strain that is being called the “most vaccine-resistant ever” after causing a surge in cases in Singapore.

The recent outbreak of infections in Singapore has been traced to XBB, a “recombinant” of the Omicron subvariants BA.2.10.1 and BA.2.75.

“Preliminary research suggests the Omicron subvariant XBB might carry a higher infection risk and be more resistant to neutralizing antibodies from booster vaccine doses and antibody drugs, but more studies are needed, according to Verywell Health.

On Sunday,  Allysia Finley wrote an opinion piece asking the real question, “Are Vaccines Fueling New Covid Variants?”

According to Finley, “it isn’t clear that XBB is any more lethal than other variants, but its mutations enable it to evade antibodies from prior infection and vaccines and existing monoclonal antibody treatments.”

Liberal Washington Post reported:

“Such rapid and simultaneous emergence of multiple variants with enormous growth advantages is unprecedented,” a Dec. 19 study in the journal Nature notes. Under selective evolutionary pressures, the virus appears to have developed mutations that enable it to transmit more easily and escape antibodies elicited by vaccines and prior infection.

The same study posits that immune imprinting may be contributing to the viral evolution. Vaccines do a good job of training the immune system to remember and knock out the original Wuhan variant. But when new and markedly different strains come along, the immune system responds less effectively.

Bivalent vaccines that target the Wuhan and BA.5 variants (or breakthrough infections with the latter) prompt the immune system to produce antibodies that target viral regions the two strains have in common. In Darwinian terms, mutations that allow the virus to evade common antibodies win out—they make it “fitter.” XBB has evolved to elude antibodies induced by the vaccines and breakthrough infections.

A New England Journal of Medicine study published last month provides more evidence of the vulnerability caused by immune imprinting. Neutralizing antibodies of people who had received the bivalent were 26 times as high against the original Wuhan variant as they were against XBB and four times as high as they were against Omicron and the BA.5 variant.

Similarly, a study this month in the journal Cell found that antibody levels of people who had received four shots were 145 times as high against the original Wuhan strain as the XBB variant. A bivalent booster only slightly increased antibodies against XBB. Experts nevertheless claim that boosters improve protection against XBB. That’s disinformation, to use their favored term.

Two years ago, vaccines were helpful in reducing severe illness, particularly among the elderly and those with health risks like diabetes and obesity. But experts refuse to concede that boosters have yielded diminishing benefits and may even have made individuals and the population as a whole more vulnerable to new variants like XBB.

Finley added that most states and countries affected by the new COVID variants have the highest vaccination and booster rates.

It might not be a coincidence that XBB surged this fall in Singapore, which has among the highest vaccination and booster rates in the world. Over the past several weeks a XBB strain has become predominant in New York, New Jersey, Connecticut and Massachusetts, making up about three-quarters of virus samples that have been genetically sequenced. The variant has been slower to take off in other regions, making up only 6% of the Midwest and about 20% in the South. The Northeast is also the most vaccinated and boosted region in the country.

Hospitalizations in the Northeast have risen too, but primarily among those over 70. One reason may be that the T-Cell response—the cavalry riding behind the front-line antibodies—is weaker in older people. The virus cannot evade T-Cells elicited by vaccines and infections as easily as it can antibodies. Because of T-Cells, younger people are still well-protected against new variants.

In case you’ve forgotten, serial liars Anthony Fauci and Brain-Dead Biden once claimed, “This is a pandemic of the unvaccinated.”

Anthony Fauci said in 2021 that unvaccinated people could ‘pose a threat to the country’s progress on the COVID-19 pandemic.’ He said Covid-19 is now an “outbreak among the unvaccinated.”

Possibly the most important study on COVID shots might explain why COVID never seems to end

Authors: Daniel Horowitz December Conservative Review published in Science Immunology

Tolerance is a good thing in most aspects of life. But when it comes to the immune system, artificially juicing up the body to create antibodies with long-term tolerance to a pathogen is a recipe for disaster. Amid thousands of papers on COVID and the vaccines, a new German paper published in Science Immunology should be the headline story this week. Although the subject matter is very dense, the implication of it is that the Pfizer shots (and possibly other mRNA spike protein shots) caused the immune system to misfire, thereby creating an endless feedback loop of viral immune escape, perpetuating the pandemic in the macro, and creating immune suppression for the individuals who received them.

The vexing question of 2022 is why the virus is even still with us to this day. Why is it that so many countries in the Pacific Rim that did so well in 2020 and 2021 now have a bigger problem in 2022 with less virulent strains of COVID? Why does it appear the pandemic will never end and so many people continue to get the virus multiple times? None of this is normal.

Wherever you turn, the most vaccinated countries are not only experiencing rampant side effects from the shots, but worse outcomes from COVID itself following their endless booster campaigns.

But even more telling than an epidemiological comparison of one nation to another is a comparison of outcomes within nations themselves between pre- and post-vaccination/booster campaign. Prior to the mass vaccination, two parts of the world largely escaped excess deaths from the virus: continental Africa and the Pacific Rim nations. Yet whereas Africa flatlined in terms of COVID deaths throughout 2021-2022, countries like Japan only experienced meaningful numbers of deaths after the mass vaccination program.

Here is a chart of the daily COVID deaths per million in Japan, a country that is super vaccinated (and mask-obsessed).

Notice how Japan is experiencing progressively worse death curves, which only began after everyone (particularly seniors) was boosted, even though Omicron is less pathogenic than the earlier strains. Japan is also the current world leader in cases per million.

Australia is a similar story:

Now contrast these two countries to Nigeria, the most populous country in Africa.

One could assert that there are some unknown factors as to why Africans appear not to die from COVID, compared to the high death rates in North America, South America, and Europe. However, the Pacific Rim countries like Japan and Australia seemed to enjoy almost as low a death rate prior to the booster campaign. After that point, Nigeria (and the rest of Africa) seemed to flatline and be done with the virus, as we would typically expect by now, while the other countries incurred skyrocketing cases and a relatively massive spike in deaths. Obviously, Nigeria’s vaccination rate is much lower than these other countries, but its booster rate is almost nonexistent.

Even within Europe, Scandinavian countries like Norway largely escaped a massive death curve during the first two years of the pandemic. That all changed in 2022. Norway now has the highest COVID death rate per million in the world.

Adding these three Omicron waves together, we see that Norway is beginning to rival the U.S. in terms of death curves. However, America is a much unhealthier country, and America experienced the death curves with the more pathogenic Wuhan and Delta strains.

If you track the number of boosters given per 100 people in some of the aforementioned countries, you will see that the current death curves track almost perfectly in a positive correlation.

Indeed, Chile now has the most deaths per capita in South America, even though the country already suffered a substantial number of deaths and should be done with the pandemic. Nigeria and the rest of Africa indeed are done with the pandemic, and the U.S., which has an average booster rate, is somewhere in the middle in terms of current COVID rates.

So, this is about a lot more than “oh, the vaccines don’t stop transmission.” They appear to proliferate it and also to worsen clinical outcomes. But why?

A group of German researchers tested for which specific antibody levels spike at what time. Specifically, they tested the Pfizer shot against the AstraZeneca shot and discovered something very concerning. Increasingly over time, and particularly with three doses of Pfizer, the immune response switched from the more neutralizing IgG1 and IgG3 antibodies to the non-neutralizing “tolerating” IgG4 antibodies:

High levels of neutralizing SARS-CoV-2-antibodies are an important component of vaccine-induced immunity. Shortly after the initial two mRNA vaccine doses, the IgG response mainly consists of the pro-inflammatory subclasses IgG1 and IgG3. Here, we report that several months after the second vaccination, SARS-CoV-2-specific antibodies were increasingly composed of non-inflammatory IgG4, which were further boosted by a third mRNA vaccination and/or SARS-CoV-2 variant breakthrough infections. IgG4 antibodies among all spike-specific IgG antibodies rose on average from 0.04% shortly after the second vaccination to 19.27% late after the third vaccination. This induction of IgG4 antibodies was not observed after homologous or heterologous SARS-CoV-2 vaccination with adenoviral vectors [emphasis added].

Why is this so important?

Importantly, this class switch was associated with a reduced capacity of the spike-specific antibodies to mediate antibody-dependent cellular phagocytosis and complement deposition. Since Fc-mediated effector functions are critical for antiviral immunity, these findings may have consequences for the choice and timing of vaccination regimens using mRNA vaccines, including future booster immunizations against SARS-CoV-2 [emphasis added].

So not only do these shots fail to produce the first line of defense antibodies known as IgA in the mucosal, something we knew from day one, but even the blood-based antibodies are increasingly the wrong type. This problem seems to get worse over time and with more doses of the shot, which correlates perfectly with numerous studies showing negative efficacy increasing over time, with more doses, and how the vaccinated take longer to clear the virus.

This topic is both very dense and fascinating. You can find clear explanations of this study about IgG4 antibodies in layman’s terms herehere, and here. But the important outcome for us from a policy standpoint is understanding the deadly subterfuge that has been foisted upon 5.5 billion people of the world and how it will be used with many more novel vaccines coming down the pipeline. The medical establishment successfully convinced the world that a vaccine is nothing more than simply stimulating an antibody response and is something that can be done within days of discovering a virus. This is why they now seek to get vaccines approved not based on accurate clinical trials and clinical outcomes but on “immunobridging” – the measuring of antibody levels. Indeed, this is how they got the bivalent booster shots and the JYNNEOS monkeypox vaccine approved and how they plan to get future shots approved.

However, merely measuring antibody levels in the abstract is meaningless and potentially masks harms to the body. God designed our bodies to create the right sort of antibodies, in the right amount, at the right time, in the right place. Any fault in any of those factors can create auto-antibodies, Trojan horse antibodies (antibody dependent disease enhancement) or a misfiring of the immune system, which is some form of original antigenic sin or pathogenic priming that teaches the body to tolerate a specific strain of the virus or respond for a wrong strain. This is why vaccines take years to develop. And this is before we even discuss the fact that these shots are not even vaccines, but are gene therapies that code your body to produce a pathogenic spike that was the result of gain-of-function research and seems to potentially damage every organ system, particularly the cardiovascular system.

In the case of the COVID shots, what the German study discovered is that over time and with increased doses it actually trains your body to tolerate rather than fight the virus it was designed to destroy. The other class of blood-based antibodies are designed to neutralize pathogens; however, the IgG4 class was specifically designed to tolerate innocuous cells (that don’t reproduce) that it repeatedly contacts, such as pollen or peanut particles. They serve an important role and help ensure that people don’t respond with excessive inflammation to everyday encounters with pollen, but to see 20% of the antibody response to SARS-CoV-2 (it was as high as 42% in those experiencing infection after boosters) be something that tolerates it is astounding … and dangerous! In other words, whereas your IgG1 or IgG3 antibodies are like the SWAT team, your IgG4 antibodies are like social workers. You don’t want social workers responding to replicating pathogens like the SARS-CoV-2 spike.

The long-term implications of this study are still unclear, but like every earth-shattering finding, this one will not be studied by governments. If this shot is really upregulating an IgG4 response for most of the population, it could easily explain why herd immunity is out the window with SARS-CoV-2. It’s literally teaching the body to not only respond to the wrong pathogen but to tolerate its existence and not remember to fight it. Also, what does this mean long-term for people who don’t create pro-inflammatory antibodies to defend against pathogens? What sort of damage is being done by not having the virus sufficiently neutralized before it invades the system so deeply?As Kilian Schober, one of the authors of the study, notes (after calling our interpretation of the study too “simplistic”),”Our findings do, however, raise some questions about how to proceed.” But in the past, we used to answer those questions before experimenting on humans, not begin to raise them (and then never answer them) after 5.5 billion people were already injected with the product.

How COVID-19 Affects the Eyes

Authors: Medical Author: Rohini Radhakrishnan, ENT, Head and Neck Surgeon Medical Reviewer: Pallavi Suyog Uttekar, MD Medicine Net

Recent studies have found that COVID-19 can affect multiple organs, including the eyes. 

In some cases, the virus can enter the body through the eyes when rubbed with infected hands or if respiratory droplets from an affected person happen to land on the eye. Ocular symptoms can occur at any stage during the course of the illness, appearing within 2 weeks of other COVID-19 symptoms and lasting less than 2 weeks. 

Medications administered to COVID-19 patients for treatment can also lead to serious side effects associated with the eyes.

5 parts of the eyes affected by COVID-19

  1. Conjunctiva: Conjunctivitis or tearing of eyes may be the first symptom of a viral infection. This is caused by inflammation of the clear mucus membrane that envelops the eye. The primary symptom of conjunctivitis is a pink or reddish color that occurs when the blood vessels in the conjunctiva become inflamed, making them more visible. Other symptoms of conjunctivitis include eye redness, irritation, soreness, itchiness, tearing, watery discharge, eyelid swelling, congestion, and chemosis. Though these symptoms rarely present as an initial symptom, it is more commonly seen in patients with severe systemic symptoms of COVID-19.
  2. Sclera: Episcleritis is a possible complication of COVID-19. It is an inflammatory condition that affects the episcleral tissue between the conjunctiva and the sclera, or white part of the eye. The link between COVID-19 and episcleritis may include vasculo-immunological factors and coagulation disorders.
  3. Retina: Retinal microvascular changes have been noted on ocular imaging in people with COVID-19. These signs were even seen in asymptomatic people with normal vital signs. Various fundoscopic findings of the retina include retinal microhemorrhages, retinal vascular tortuosity, retinal vascular occlusion, cotton wool spots, and hyper-reflective plaques in the ganglion cell-inner plexiform layer. Retinal involvement of the infection often presents in the form of a decrease in vision or blindness.
  4. Optic nerve: A wide variety of neuro-ocular symptoms have been found in people with COVID-19 infection. The hypotheses proposed for this include direct neuronal attack by viral particles, endothelial cell dysfunction leading to ischemia, and coagulopathy, or a widespread inflammatory cytokine storm induced by the virus. Optic neuritis, which is inflammation of the optic nerve, has been noted in several cases. The condition leads to a sudden loss of vision, relative afferent pupillary defect, pain with eye movements, and optic disc edema.
  5. Orbit: Mucormycosis, a severe fungal infection, presents with symptoms that include eye swelling or redness, double vision, loss of vision, eye pain, and drooping eyelid. The infection mainly affects individuals with a compromised immune system along with decreased CD4+ and CD8+ lymphocytes, those with comorbidities (such as diabetes mellitus and decompensated pulmonary functions), and those on immunosuppressive therapy (corticosteroids).

What are the effects of COVID-19 medications on eyes?

Medications that have been used to treat COVID-19 have been associated with ocular toxicities:

  • Chloroquine and hydroxychloroquine, when used long-term, can lead to retinal toxicity
  • Lopinavir or ritonavir can lead to the reactivation of autoimmune conditions
  • Ribavirin has been seen to cause retinopathy, retinal vein occlusion, serous retinal detachment, and nonarteritic ischemic optic neuropathy
  • Interferon has been reported to cause retinopathy, conjunctivitis, uveitis, optic neuropathy, corneal ulcers, and epithelial defects
  • Tocilizumab has been associated with retinal hemorrhages and cotton wool spots
  • Systemic corticosteroids are known to cause cataractsglaucoma, and central serous chorioretinopathy

How to protect your eyes from COVID-19 infection

  • Avoid rubbing your eyes
  • Use a clean tissue to instead of fingers if your eyes are itchy
  • Stock up on eye care supplies and medications
  • Wear glasses instead of contact lenses during the pandemic
  • Do not delay treatment for serious eye issues
  • Consider wearing safety goggles when caring for COVID-19 patients

Risk of rare heart inflammation may be higher after Moderna than Pfizer COVID vaccine

Authors: ry Van Beusekom | News Writer | CIDRAP News  |  Nov 08, 202

Myocarditis and pericarditis are rare after mRNA COVID-19 vaccination, but rates of the inflammatory heart conditions were twofold to threefold higher after receipt of the second dose of the Moderna vaccine than after the Pfizer/BioNTech formulation, suggests a head-to-head comparison in Canadian adults.

The findings of the observational, population-based analysis were published yesterday in the Journal of the American College of Cardiology.

Researchers from the British Columbia Centre for Disease Control in Vancouver led the study on the diagnosis of myocarditis, pericarditis, or myopericarditis during a hospitalization or emergency department visit within 21 days after receipt of the second mRNA COVID-19 vaccine dose from Jan 1 to Sep 9, 2021. During that period, more than 870,000 Moderna and 2.2 million Pfizer second doses were administered in British Columbia.

Myocarditis is inflammation of the heart muscle, pericarditis is inflammation of the membrane surrounding the heart, and myopericarditis is an extension of pericardial inflammation into the heart muscle.

Risk after COVID infection higher

Rates of myocarditis (31 cases; 35.6 per million second doses) and pericarditis (20; 22.9 per million) were higher after the Moderna vaccine than after Pfizer (28; 12.6 per million and 21; 9.4 per million, respectively). For comparison, rates of myocarditis in the general population during the same period were 2.0 per million in vaccinees 18 to 39 years old and 2.2 per million in older adults.

Relative to the Pfizer vaccine, Moderna was tied to significantly higher chances of myocarditis (adjusted odds ratio [aOR], 2.78; 95% CI, 1.67 to 4.62), pericarditis (aOR, 2.42; 95% CI, 1.31 to 4.46), and myopericarditis (aOR, 2.63; 95% CI, 1.76 to 3.93). The link between Moderna and myocarditis was strongest for men (aOR, 3.21; 95% CI, 1.77 to 5.83) and the younger age-group (aOR for 18 to 39 years, 5.09; 95% CI, 2.68 to 9.66).

A person choosing an mRNA vaccine should “consider the self-limiting and mild nature of most myocarditis events, benefits provided by vaccination, higher effectiveness of the Moderna vaccine against infection and hospitalization [found in prior studies], and the apparent higher risk of myocarditis following COVID-19 infection than with mRNA vaccination,” lead author Naveed Janjua, MBBS, PhD, said in an American College of Cardiology news release.

In a related commentary, Guy Witberg, MD, MPH, and Ilan Richter, MD, MPH, both of Rabin Medical Center in Petah-Tikva, Israel, said the study provides further evidence that heart inflammation is rare after both vaccines.

It “should help put to rest ‘vaccine hesitancy’ due to concerns over cardiac adverse events,” they wrote. “Its results have practical policy implications: for a substantial segment of the population suffering from cardiovascular disease, especially those with left ventricular dysfunction, in whom minimizing risk of myocardial insult is crucial, these data give a strong argument to preferentially use the BNT162b2 [Pfizer] vaccine over mRNA-1273 [Moderna].”

Case for Immediate Suspension of All Covid Shots: Peer-reviewed Study

Authors: Veronika Kyrylenko New American Sptember 27, 2022

Dr. Malhotra’s two-part peer-reviewed article titled “Curing the pandemic of misinformation on COVID-19 mRNA vaccines through real evidence-based medicine” (available here and here) was presented during a press conference organized by the World Council for Health on Tuesday, and was streamed live by The New American.

Corruption of Medicine

Coming from the crème de la crème of the British medical establishment, Dr. Malhotra, vaccinated himself, first examined the “root cause” of the vaccines’ failure and the overall decline of public health. That, he believes, is a capture of the healthcare authorities and a part of the medical profession, including major medical journals, by large pharmaceutical companies. The profound corruption undermines the principles of ethical evidence-based medical practice and informed consent, argued Malhotra.

Citing a 2021 research paper by Dr. John Ioannidis, “How to Survive the Disinformation Mess,” Dr. Malhotra pointed out that “most published research is not reliable, offers no benefit to patients, or is not useful for decision makers.” One would assume that his or her doctor, who swore the Hippocratic Oath, would certainly recognize the issue and warn about it — but no, said the doctor, “most healthcare professionals ARE NOT AWARE of this problem,” since they often lack the necessary skills to properly evaluate such research papers. (Emphasis in original.) Most disturbingly, the people at the very top of the clinical and academic leadership are “ignorant” of this fact.

Not surprisingly, the doctor continued, “the greater the financial and other prejudices in a scientific field, the less likely the research findings are to be true.”

One should not expect pharmaceutical corporations to care about individuals’ personal well-being and health. “Drug companies have a legal obligation to produce a profit for their shareholders. They do not have a legal obligation to give you the best treatment, even though most of us would like that to be the case,” Dr. Malhotra said, proceeding to walk the audience through the scandalous history of the drug industry, marred by scientific fraud and corporate crimes.

Later in his speech, he touched on how the enormous amount of power transforms the psyches of corporate executives, making them practically inhumane.

Worse Than the Disease

Dr. Malhotra then presented overwhelming clinical evidence that vaccines cause more harm than Covid. In other words, he proved that the cure is actually worse than the disease.

As the number of Brits suffering heart attacks was increasing during the year 2021, with one such victim being Dr. Malhotra’s father, the doctor started urging his colleagues to closely look at the evidence of heart issues caused or aggravated by the shots.

The doctor cited his discovery of the November 8, 2021 article entitled “Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning” by cardiac surgeon Stephen Gundry. The study concluded that mRNA vaccinations “dramatically increase inflammation on the endothelium,” which is a single layer of cells that lines the interior surface of blood and lymphatic vessels. That “may account for the observations of increased thrombosis, cardiomyopathy, and other vascular events following vaccination,” per the study’s abstract.

Dr. Malhotra explained then that what shots did was aggravate the underlying heart disease, increasing the risk of heart attack from 11 percent in five years to 25 percent, which the doctor called a “huge increase.”

Do the benefits of getting a shot outweigh the risk?

Not at all, maintained the doctor.

First, vaccines do not prevent infection; this has been admitted at the highest levels of healthcare agencies in the West. For example, the U.S. Food and Drug Administration published back in May 2021 that “Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination,” meaning that the antibodies that a vaccinated person produces are unreliable protection! Yet, all clinical studies done by the vaccine makers quote “antibody levels” as proof that their shots work. That includes the latest trials of the booster that presumably targets the Omicron strain, which measured antibodies in eight mice. Malhotra called it a “miscarriage of medical science.”

Furthermore, real-world data shows that shots do not reduce one’s chances of landing in the hospital, since to prevent one single Covid death, thousands, if not tens and even hundreds of thousands, of people must receive a vaccine. And many of those who are vaccinated will have serious adverse reactions. Per Malhotra’s paper, “the MHRA [the Medicines and Healthcare Products Regulatory Agency of the U.K.] figures show around 1 in 120 suffering a likely adverse event that is beyond mild.”

Shouldn’t healthcare authorities and regulators be vigilant about such life-and-death issues? Isn’t that their primary duty?

In theory, yes. But in practice, they are also captured by Big Pharma, and in many countries around the world, most of the funding for regulatory agencies comes from the pharmaceutical industry. In particular, the FDA receives as much as 65 percent of its funding from the very companies it regulates, notes Malhotra.  

The analysis of real-world data on the vaccines allowed the doctor to come to the key following conclusions:

1. The shots offer no protection from Covid infection.

2. The shots did not reduce Covid mortality or all-cause mortality in the original randomized control studies.

3. As suggested by those studies, one in 800 mRNA vaccine recipients would be seriously harmed by the shot. That’s greater than the likelihood of being hospitalized with Covid.

4. To prevent one Omicron-related death in those over 80 years of age, 7,300 people in that age group must be vaccinated. For those under 50, the ratio is one to 10,000.

5. The shots are linked to an unprecedented number of reported adverse reactions.

6. According to real-world data, the rate of harm requiring hospitalization is close to one in 1,000 within a couple of months of the mRNA jab, which is likely a “significant underestimate.”

Dr. Malhotra’s observations were supported by Drs. Tess Lawrie and Ryan Cole.

Dr. Cole, participating virtually, supports Dr. Malhotra’s calls for immediate and complete suspension of Covid shots. Cole explained how the shots code the most toxic part of the virus — the spike protein — into body cells. That protein circulates in our bodies for weeks, and then is produced by our cells for at least 60 days.

What happens then? According to Dr. Cole, some of the spike-induced harms includes the following:

  • Viral reactivation;
  • DNA mismatch repair inhibition;
  • Neurologic damage;
  • Mitochondrial damage;
  • Heart damage;
  • Immune inhibition (original antigenic sin);
  • Antibody-dependent cellular cytotoxicity;
  • Decreased sperm counts and motility,
  • Hormonal dysregulation, etc.

The spike protein is to blame for increased rates of cancer, cardiac arrests, and blood clotting, argued the doctor. It is the Covid shots that are causing excess mortality in highly vaccinated countries.

Dr. Lawrie, a co-founder of the WCH, referenced the WCH report on the abundant pharmacovigilance data on WHO VigiAccess, CDC VAERS, EudraVigilance, and the U.K. Yellow Card Scheme to suspend the use of experimental Covid gene therapeutics. 

After the press conference, Dr. Lawrie said to The New American,

Doctors can no longer ignore the fact that they absolutely must join the conversation on vaccine injury linked with these Covid vaccines — a novel technology that has been widely rolled out and never proven safe in animals let alone healthy men, women, and children. They have been deceived and incentivized to turn a blind eye. Now is the time to speak up, and not a minute too soon.

Drs. Malhotra, Cole, and Lawrie are not alone in their calls. Earlier this month, more than 400 scientists and medical professionals from more than 34 countries signed the “Declaration of International Medical Crisis Due to the Diseases and Deaths Co-related to the ‘COVID-19 Vaccines.’” 

Speaking with The New American on the matter, one of the signatories of the Declaration, Dr. Naseeba Kathrada of the WCH, said that practicing physicians around the world are seeing an “unheard of” number of diseases and deaths in healthy people linked to the shots.

European Medicines Agency Recommends Adding “Heavy Menstrual Bleeding” to Pfizer and Moderna’s COVID Shots Product Information as a Side Effect

By Jim Hoft Published October 28, 2022  TGP

On Friday, the European Medicines Agency (EMA) recommended adding “heavy menstrual bleeding” to the list of side effects caused by Pfizer and Moderna’s mRNA shots.

In April 2021, The Gateway Pundit first reported on the tens of thousands of women who complained about irregular menstruation after taking the COVID vaccines.

Women who received the Covid vaccine reported to have spotting in between their cycles, shortened cycles, and lengthened cycles.

However, anyone who spoke about a link between Covid vaccines and menstrual problems/fertility issues was labeled a “conspiracy theorist.”

Earlier this year, the EMA’s risk assessment committee announced that it would review reports of menstruation irregularities after thousands of women reported changes to their monthly cycle after getting the COVID vaccine.

“After reviewing the available evidence, the PRAC decided to request an in-depth evaluation of all available data, including reports from spontaneous reporting systems, clinical trials, and the published literature,” according to the news release.

“At this stage, it is not yet clear whether there is a causal link between the COVID-19 vaccines and the reports of heavy periods or amenorrhea. There is also no evidence to suggest that COVID-19 vaccines affect fertility,” the agency said.

Now, the regulatory body recommended including “heavy menstrual bleeding” as an adverse effect on the list of product warnings and precautions.

Read the EMA statement:

The PRAC has recommended that heavy menstrual bleeding should be added to the product information as a side effect of unknown frequency of the mRNA COVID-19 vaccines Comirnaty and Spikevax.

Heavy menstrual bleeding (heavy periods) may be defined as bleeding characterised by an increased volume and/or duration which interferes with the person’s physical, social, emotional and material quality of life. Cases of heavy menstrual bleeding have been reported after the first, second and booster doses of Comirnaty and Spikevax.

The PRAC finalised the assessment of this safety signal after reviewing the available data, including cases reported during clinical trials, cases spontaneously reported in Eudravigilance and findings from the medical literature.

After reviewing the data, the Committee concluded that there is at least a reasonable possibility that the occurrence of heavy menstrual bleeding is causally associated with these vaccines and therefore recommended the update of the product information.

The available data reviewed involved mostly cases which appeared to be non-serious and temporary in nature.

Menstrual disorders in general are quite common and they can occur for a wide range of reasons. This includes some underlying medical conditions. Any person who experiences postmenopausal bleeding or is concerned about a change in menstruation should consult their doctor.

There is no evidence to suggest the menstrual disorders experienced by some people have any impact on reproduction and fertility. Available data provides reassurance about the use of mRNA COVID-19 vaccines before and during pregnancy. A review carried out by EMA’s Emergency Task Force showed that mRNA COVID-19 vaccines do not cause pregnancy complications for expectant mothers and their babies, and they are as effective at reducing the risk of hospitalisation and deaths in pregnant people as they are in non-pregnant people.

The Committee reiterates that the totality of data available confirms that the benefits of these vaccines greatly outweigh the risks.

Healthcare professionals and patients are encouraged to continue to report cases of heavy menstrual bleeding to their national authorities.

The PRAC will continue to monitor for cases of this condition and will communicate further if new recommendations are warranted.

New onset and exacerbation of psoriasis after COVID-19 vaccination

Authors: Nancy Wei, BA,a,∗ Mindy Kresch, BS,b Emily Elbogen, PA-C,c and Mark Lebwohl, MDc JAAD Case Rep. 2022 Jan; 19: 74–77. Published online 2021 Nov 29. doi: 10.1016/j.jdcr.2021.11.016 PMCID: PMC8628636PMID: 34869811


The messenger RNA (mRNA)-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) vaccines were granted emergency use authorization during the ongoing COVID-19 pandemic by the United States Food and Drug Administration in December 2020.1 An adenoviral vector vaccine Ad26.COV2.S (Janssen) was similarly approved for use in February 2021.1 To date, over 168.4 million people in the United States of America have been fully vaccinated.2

Psoriasis is a chronic, inflammatory skin condition that an estimated 7.55 million adults live with nationwide.3 As patients on immunosuppressive therapy were excluded from vaccine clinical trials, there is no data on the efficacy and safety of the novel vaccines in this patient population. While uncommon, a potential association has previously been documented between new onset or exacerbation of psoriasis in response to vaccination against Bacillus Calmette-Guérin (BCG), influenza, tetanus-diphtheria, and pneumococcal polysaccharide.456789101112 This response has been documented in inactivated, attenuated, toxoid, and polysaccharide types of vaccines but not in the novel mRNA vaccine clinical trial data.

We present a series of postvaccination exacerbation and new-onset psoriasis and review similar reports from publicly available nationwide Center for Disease Control (CDC) Vaccine Adverse Events Reporting System (VAERS) data. As vaccination against COVID-19 continues worldwide, it is essential to recognize and understand the possible adverse events in psoriasis patients.


A retrospective case series study was performed at the Department of Dermatology at Mount Sinai Hospital in New York City to assess new-onset psoriasis or exacerbation of existing disease after COVID-19 vaccination. All patients were referred to the Mount Sinai Dermatology Service from March to August 2021. Patient demographic information, medical history, medications, allergies, vaccine manufacturer, latency, treatment, and outcomes were collected and reviewed.

A retrospective review of the CDC VAERS of all reports from December 2020 to August 2021 was conducted using the search terms “psoriasis,” “guttate psoriasis,” and “erythrodermic psoriasis.” Reports that were related to a non-COVID 19 vaccine, such as vaccines for herpes zoster or influenza, were excluded from the analysis. Reports that did not provide enough clinical information, such as the time to onset, clinical description, symptoms, or confirmation by laboratory findings, biopsy, or diagnosis by a physician, were excluded.


All 7 patients (median [range], 68 [27-89] years; 57.1% men) experienced new-onset or flares in psoriasis after receiving COVID-19 vaccination. Six patients received the Moderna vaccine, while 1 received the Pfizer vaccine. The main characteristics of these patients are displayed in Table I. Only 1 patient had no history of psoriasis before vaccination. One patient reported a severe flare in psoriasis 7 days after the first dose of the vaccine and a second exacerbation 7 days after her second dose. All the other patients only experienced symptoms after the second dose. Five out of 7 patients tested positive for prior COVID-19 infection. The median latency for the onset of flare or new-onset psoriasis was 24 days following the administration of the second vaccine dose (range, 6-90 days).

Table I

Main characteristics of patients with new or exacerbated psoriasis after receiving COVID-19 vaccine

Patient no.Age (y)SexVaccineOnsetPsoriasis symptomsPhysical examinationTreatmentOutcomePrevious COVID-19
176MModerna62FlareScalp, inner ears, chest, arms, legs, buttocks
55% BSA
NBUVB phototherapy
289MModerna24New onsetScalp, torso, arms, legs
60% BSA
Ixekizumab Acitretin 25 mgResolvedNo
369MModerna21FlareFace, torso, groin, arms, legs
60% BSA
Apremilast, tildrakizumabResolvedYes
468FModerna6FlareScalp, arms, legs, feet
10% BSA
567MModerna60FlareScalp, trunk, arms, legs, feet
35% BSA
Tildrakizumab, clobetasolImprovedYes
652FModerna7FlareScalp, face, trunk, arms
30% BSA
Risankizumab, clobetasol, mometasone, triamcinoloneImprovedYes
727FPfizer90FlareScalp, elbow, thigh, knee
<10% BSA

Open in a separate window

BSA, Body surface area; F, female; M, male.

Days after second vaccination.

Narrow-band ultraviolet B radiation.

Patient experienced flare 7 days after the first vaccination, and a second flare 7 days after the second vaccination.

The CDC VAERS database search revealed 79 patients (mean ± SD age, 56.2 ± 14.9 years; 53 [67.1%] women) who experienced new onset or exacerbation of psoriasis after the COVID-19 vaccines. The summary of demographics and clinical data from the CDC VAERS data review is described in Table II. A total of 57 (72.2%) patients had known psoriasis, and 22 (27.8%) reported new-onset psoriasis. Of the patients with newly diagnosed psoriasis, 6 were determined to be of the guttate subtype. Overall, the majority had received the Pfizer-BioNTech vaccine (38, 48.1%), followed by the Moderna (34, 43.0%) and the Janssen (7, 8.9%) vaccine.

Table II

Demographic and clinical characteristics of subjects from the Center for Disease Control Vaccine Adverse Events Reporting System reporting psoriasis following COVID-19 vaccination

Total no. of subjects79
Sex, n (%)
 Female53 (67.1)
 Male25 (31.6)
 Unknown1 (1.3)
Age (y), mean ± SD56.2 ± 14.9
Vaccine, n (%)
 BNT162b2 (Pfizer-BioNTech)38 (48.1)
 mRNA-1273 (Moderna, Inc)34 (43.0)
 Ad26.COV2.S (Janssen Pharmaceuticals, Inc)7 (8.9)
Symptom code, n (%)
 Psoriasis36 (45.6)
 Condition aggravated27 (34.2)
 Biopsy11 (13.9)
 Guttate psoriasis4 (5.1)
 Autoimmune condition1 (1.3)
Days to onset, n (%)
 0-7 days45 (57.0)
 8-27 days15 (19.0)
 ≥28 days14 (17.7)
 Unspecified5 (6.3)
New-onset psoriasis, n (%)
 Guttate6 (27.3)
 Plaque16 (72.7)
Exacerbation of known disease, n (%)
 Guttate1 (1.8)
 Plaque56 (98.2)

Open in a separate window

Includes “biopsy,” “biopsy skin,” and “biopsy skin abnormal.”

The days to symptom onset ranged from 0 to 65 days after the first injection (median, 6 days). For the 7 recipients of the Janssen vaccine, the days to symptom onset ranged from 4 to 17 days. Of the 56 patients whose symptoms began after the first dose of the Pfizer-BioNTech or Moderna vaccines, 5 patients reported worsening psoriasis after the second dose as well. Fourteen (17.7%) of all patients reported onset of symptoms after the second dose of the Pfizer-BioNTech or Moderna vaccines only.


We report 7 patients who experienced an exacerbation of known psoriasis and one patient with new-onset psoriasis following vaccination against COVID-19 with the Pfizer and Moderna vaccines. Six of our patients presented with their symptoms after the second dose of the vaccine only, with 1 patient reporting flares after each dose. Most of our patients had previously tested positive for COVID-19 infection. While limited due to the self-reported nature of the database, the CDC VAERS data also reported numerous patients who experienced both new onset and worsening of known psoriasis following Moderna, Pfizer-BioNTech, and Janssen vaccines. Unlike our cohort, most of the CDC patients (60, 76%) experienced their symptoms after the first dose or within 28 days of the vaccine, with 5 who reported worsening after receiving a second dose.

Previous studies have reported influenza (H1N1), tetanus-diphtheria, BCG, and pneumococcal pneumonia vaccination as a triggering factor for new-onset or flare of psoriasis.456789101112 To date, there is 1 published case report describing a psoriasis flare-up 5 days after the second dose of the Pfizer-BioNTech vaccine.13 Potential cutaneous adverse events following COVID-19 vaccination were described in a registry-based study of 414 cases and included delayed large local reactions, local injection-site reactions, urticarial eruptions, morbilliform reactions, pernio, cosmetic filler reactions, herpes zoster, herpes simplex flares, and pityriasis rosea-like reactions.14 However, only 2 psoriasis flares were recorded in this cohort, which the authors noted to be rare.

Currently, there is no well-understood pathologic mechanism for new-onset or flares of psoriasis following vaccination. Previous studies have demonstrated a significant increase in interleukin 6 production and, in turn, T helper 17 (Th17) cell development after BCG, tetanus-diphtheria, and influenza vaccines.4 Additionally, elevated Th17 responses have been observed in patients with severe COVID-19 disease.15 As increasing evidence points to Th17 cells having a role in the pathogenesis of psoriatic disease, it can be hypothesized that perhaps the COVID-19 mRNA vaccines induce elevation of interleukin 6 and Th17 cells, which can contribute to the onset or flare of new psoriasis in a subset of patients.

To determine the incidence of flares or new-onset psoriasis for each COVID vaccine, we encourage health care professionals to submit cases to the American Academy of Dermatology registry (available at As the world continues to undergo COVID-19 vaccination and booster vaccine shots in the near future, further studies should be carried out to investigate the potential association between new-onset and exacerbation of psoriasis and COVID-19 vaccines.


The case series presented was from a small sample size in a single geographic location during a short period of time, which limits its generalizability. The CDC VAERS database collects self-reported symptoms from patients and physicians and is thus subject to reporting bias if they believe that the vaccine was the cause. The data may include incomplete, inaccurate, coincidental, and unverified information.


1. COVID-19 vaccines. US Food and Drug Administration.

2. COVID data tracker. Centers for Disease Control and Prevention. Data as of: August 15, 2021 6:00 am ET.

3. Armstrong A.W., Mehta M.D., Schupp C.W., Gondo G.C., Bell S.J., Griffiths C.E.M. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940–946. doi: 10.1001/jamadermatol.2021.2007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Gunes A.T., Fetil E., Akarsu S., Ozbagcivan O., Babayeva L. Possible triggering effect of influenza vaccination on psoriasis. J Immunol Res. 2015;2015:258430. doi: 10.1155/2015/258430. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Raaschou-Nielsen W. Psoriasis vaccinalis; report of two cases, one following BCG vaccination and one following vaccination against influenza. Acta Derm Venereol. 1955;35(1):37–42. [PubMed] [Google Scholar]

6. Sbidian E., Eftekahri P., Viguier M., et al. National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines. Dermatology. 2014;229(2):130–135. [PubMed] [Google Scholar]

7. Shin M.S., Kim S.J., Kim S.H., Kwak Y.G., Park H.J. New onset guttate psoriasis following pandemic H1N1 influenza vaccination. Ann Dermatol. 2013;25(4):489–492. [PMC free article] [PubMed] [Google Scholar]

8. Shi C.R., Nambudiri V.E. Widespread psoriasis flare following influenza vaccination. Vaccine. 2017;35(36):4785–4786. [PubMed] [Google Scholar]

9. Macias V.C., Cunha D. Psoriasis triggered by tetanus-diphtheria vaccination. Cutan Ocul Toxicol. 2013;32(2):164–165. [PubMed] [Google Scholar]

10. Yoneyama S., Kamiya K., Kishimoto M., Komine M., Ohtsuki M. Generalized exacerbation of psoriasis vulgaris induced by pneumococcal polysaccharide vaccine. J Dermatol. 2019;46(11):e442–e443. [PubMed] [Google Scholar]

11. Grafanaki K., Vryzaki E., Georgiou S., Liga M. Double trouble: influenza and pneumococcal vaccine exacerbation of psoriasis in a new-onset polycythemia vera patient. J Dermatol. 2020;47(7):e263–e264. [PubMed] [Google Scholar]

12. Munguía-Calzada P., Drake-Monfort M., Armesto S., Reguero-Del Cura L., López-Sundh A.E., González-López M.A. Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center. Dermatol Ther. 2021;34(1):e14684. doi: 10.1111/dth.14684. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Krajewski P.K., Matusiak Ł., Szepietowski J.C. Psoriasis flare-up associated with second dose of Pfizer-BioNTech BNT16B2b2 COVID-19 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021;35(10):e632–e634. doi: 10.1111/jdv.17449. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. McMahon D.E., Amerson E., Rosenbach M., et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55. doi: 10.1016/j.jaad.2021.03.092. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Wu D., Yang X.O. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368–370. doi: 10.1016/j.jmii.2020.03.005. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Psoriasis Flares in Patients With COVID-19 Infection or Vaccination: A Case Series

Authors: Hemali ShahAna C. Busquets

Published: June 16, 2022 (see history) DOI: 10.7759/cureus.25987 Cite this article as: Shah H, Busquets A C (June 16, 2022) Psoriasis Flares in Patients With COVID-19 Infection or Vaccination: A Case Series. Cureus 14(6): e25987. doi:10.7759/cureus.25987


Much of the literature involving COVID-19 and chronic inflammatory dermatological conditions have focused on the safety of immunomodulatory therapy in the setting of this highly infectious virus. While general mortality associated with the infection and vaccine has been studied in depth, the effects of the virus and vaccine on inflammatory skin disease states have not been. It is well known that psoriasis can be triggered by stress, infection, certain medications, and, although not as common, vaccinations. Further, existing literature has briefly commented on psoriasis flares after COVID vaccination, but these have not touched on flares among their patients’ current therapy, nor flares after COVID infection. In this case report, we report five cases observed at our institution over the last year of either new-onset psoriasis or flares of previously well-controlled psoriasis shortly after infection with COVID-19 or COVID-19 vaccination, with no other identifiable triggers. These cases can serve to raise awareness of issues related to managing stubborn psoriatic flares and bring to the forefront conversations that are likely to arise with our patients regarding the risks and benefits of COVID vaccination and boosters. While the definitive etiology of the association between COVID and psoriasis remains unclear, it is important that the dermatologic community be aware when evaluating patients with new-onset or worsening psoriasis as we move forward in times of this COVID-19 era.


Much of the literature involving COVID-19 and chronic inflammatory dermatological conditions have focused on the safety of immunomodulatory therapy in the setting of this highly infectious virus. While general mortality associated with the infection and vaccine has been studied in depth, the effects of the virus and vaccine on inflammatory skin disease states have not been. Certainly, there are possible adverse effects of COVID vaccination with no long-term sequelae that are accepted as risks when compared to the severity of infection, but these have not been widely addressed in the literature [1,2].

It is well known that psoriasis can be triggered by stress, infection, certain medications, and, although not as common, vaccinations [1]. In this series, we report five cases observed at our institution over the last year of either new-onset psoriasis or flares of previously well-controlled psoriasis shortly after infection with COVID-19 or COVID-19 vaccination, with no other identifiable triggers. With this series, we hope to add to the limited existing literature by revealing that flares of psoriasis can occur in both untreated and chronically managed patients and as the result of both infection and vaccination.

Case Presentation

The first of our patients is a 22-year-old male who was well controlled on ustekinumab for four years. He was unvaccinated when he contracted a COVID-19 infection in December 2020. He developed a severe flare two weeks later that was not responsive to ustekinumab, risankizumab, or secukinumab, which is his current therapy. Further, he had an influenza infection in February 2021, which significantly worsened his flare. To date, his rash remains uncontrolled with plans to change therapy underway.

Next is a 70-year-old COVID-vaccinated male well controlled on apremilast for one year. He contracted a COVID-19 infection in August 2021 and flared one week later on his hands, left greater than right, which was similar to his initial presentation. His flare lasted four weeks and subsided without any additional therapeutic intervention. He had previously been vaccinated against COVID months earlier with no issues and received his booster shot one week prior to this office visit with no further flares.

The third patient is a 40-year-old COVID-vaccinated female with psoriasis refractory to secukinumab. She was then treated with adalimumab with improvement, but her course was then complicated by frequent urinary tract infections and worsening inverse psoriasis at the onset of the COVID pandemic. These isolated issues were managed and resolved with oral antibiotics and topical therapy. Because she was stable, she discontinued her immunobiological therapy due to personal concerns about tumor necrosis factor (TNF)-inhibitor therapy during the pandemic. She remained clear for seven months. Within two weeks of receiving her COVID booster vaccination, her psoriasis and psoriatic arthritis began to flare, with plaques re-appearing on her thighs and forearms, as well as below her breasts, leading to a body surface area (BSA) involvement similar to her refractory period presentations while on secukinumab. Plans to restart a TNF inhibitor are underway.

The fourth patient is a 51-year-old COVID-vaccinated female with longstanding, uncontrolled psoriasis for 20 years. She had been completely clear and stable on risankizumab for 2.5 years. She was infected with COVID despite being vaccinated months prior with no issues and noted her psoriasis began to flare several weeks after becoming infected. Her BSA involvement was limited enough to manage with mid- and high-potency topical corticosteroids.

The last patient is a 34-year-old COVID-vaccinated male who presented with new-onset psoriasis involving his scalp, ankles, knees, hips, and nails within one month of COVID infection. He had previously been vaccinated against COVID months prior to infection with no issues. His case is being successfully managed with topical clobetasol foam and calcipotriene cream. 


The hallmark of psoriasis is sustained inflammation led by a T-cell-driven autoimmune response with elevated levels of interleukin (IL)-23, IL-17, and TNF-a [1,3]. Known psoriasis triggers, such as infections, can indirectly affect the interplay of these mediators. Psoriasis has also been associated with higher levels of angiotensin-converting enzyme type 2 (ACE2) than the general population. COVID-19 spike protein has been noted to have a high affinity for ACE2 receptors. This could be a possible causal mechanism of reactivity in the association between psoriasis and COVID-19 infection and vaccination [4].

Vaccination is an uncommon trigger for psoriasis flares. However, there have been reports of psoriasis flares after vaccination for influenza, pneumococcal pneumonia, and yellow fever [1]. With the recent increase in mRNA vaccinations, McMahon et al. studied (N=414) cutaneous reactions after COVID-19 vaccination and found only two cases of psoriasis flares [5]. Wei and colleagues reported seven cases at their institution as well as investigated 79 cases reported in the Vaccine Adverse Events Reporting System. This report, however, did not specify whether patients were controlled on therapy prior to flare. Other studies have also shown that while patients have flared with vaccination, there have not been documented flares among patients on biologic therapy. Rather, this has been assessed and deemed to not be a correlation [6]. The patients observed at our institution, however, flared with infection or vaccination while on current biologic therapy in three out of five cases.

Psoriasis is also known to be triggered by infections. For example, the streptococcal infection has been associated with new-onset or flares of guttate psoriasis, which has been well reported in the literature [7]. A review article by Aram et al. found that flares of psoriasis were common after COVID infection, but these were largely attributed to the use of anti-malarial drugs or discontinuation of immunomodulatory therapy secondary to infection [8]. Our patients, in contrast, flared without the use of these medications or concurrent discontinuation of long-term therapy.

The pandemic has been a cause for irregular dermatological consultations and difficulty obtaining medications, and it has led to significant stress in the lives of many individuals, from social isolation to concerns about employment to the inability to seek medical care in a timely manner [9]. Psoriasis is often triggered by stress, including psychosocial stressors as well as physical stress on the body, which is important to note when addressing flares during the pandemic. However, all of our patients with these flares denied significant life or psychosocial stressors around the time preceding the onset of their psoriasis.

These cases are interesting for several reasons. First, the psoriasis flares noted occurred secondary to both COVID infection and vaccination. This suggests that one’s immune response to the virus is being replicated during vaccination; thus, these psoriatic manifestations are more certainly a result of the immune response rather than a direct viral assault. We, therefore, can likely continue to expect similar skin reactions whether a patient gets infected with COVID or receives the vaccination. Second, reactions happened in both stable, treated patients, as well as undiagnosed patients. It is possible that the hyper-inflammatory state induced by COVID-19 causes an upregulation of previously controlled cytokines, unmasking a genetic predisposition for psoriasis and that treatment with targeted anti-psoriatic systemic medication does not necessarily mitigate this risk.


These cases can serve to raise awareness of issues related to managing stubborn psoriatic flares and bring to the forefront conversations that are likely to arise with our patients regarding the risks and benefits of COVID vaccination and boosters. Further, our cases show that these flares can occur in previously stable patients treated with immunobiologic therapies. While the definitive etiology of the association between COVID and psoriasis remains unclear, it is important that the dermatologic community be aware when evaluating patients with new-onset or worsening psoriasis as we move forward in times of this COVID-19 era, and we urge our colleagues to contribute to the literature surrounding this topic.


  1. Munguía-Calzada P, Drake-Monfort M, Armesto S, Reguero-Del Cura L, López-Sundh AE, González-López MA: Psoriasis flare after influenza vaccination in Covid-19 era: a report of four cases from a single center. Dermatol Ther. 2021, 34:e14684. 10.1111/dth.14684
  2. Wei N, Kresch M, Elbogen E, Lebwohl M: New onset and exacerbation of psoriasis after COVID-19 vaccination. JAAD Case Rep. 2022, 19:74-7. 10.1016/j.jdcr.2021.11.016
  3. Rendon A, Schäkel K: Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:1475. 10.3390/ijms20061475
  4. Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhahfar S: Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)?. J Dermatolog Treat. 2022, 33:1175-6. 10.1080/09546634.2020.1782819
  5. McMahon DE, Amerson E, Rosenbach M, et al.: Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021, 85:46-55. 10.1016/j.jaad.2021.03.092
  6. Skroza N, Bernardini N, Tolino E, et al.: Safety and impact of anti-COVID-19 vaccines in psoriatic patients treated with biologics: a real life experience. J Clin Med. 2021, 10:3355. 10.3390/jcm10153355
  7. Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet. 2007, 370:263-71. 10.1016/S0140-6736(07)61128-3
  8. Aram K, Patil A, Goldust M, Rajabi F: COVID-19 and exacerbation of dermatological diseases: a review of the available literature. Dermatol Ther. 2021, 34:e15113. 10.1111/dth.15113
  9. Rob F, Hugo J, Tivadar S, et al.: Compliance, safety concerns and anxiety in patients treated with biologics for psoriasis during the COVID-19 pandemic national lockdown: a multicenter study in the Czech Republic. J Eur Acad Dermatol Venereol. 2020, 34:e682-4. 10.1111/jdv.16771

25% Of People Who Received Covid-19 Vaccination Missed Work Or Reported A “Serious Event” Affecting Their Normal Life Functions, According To CDC Data

Authors: NICOLE DOMINIQUE· Oct 5th 2022

Official data from the CDC has been released due to court orders, as stated by lawyer Aaron Siri. The findings show that 25% of people who got the shot (from a database of 10 million) couldn’t perform normal activities and had to miss work or school afterward.

Lawyer Aaron Siri has successfully obtained reports from the CDC after the Informed Consent Action Network sued the organization twice. The court order required the CDC to release crucial information on the vaccine’s safety. The data is gathered from 10 million individuals who utilized the CDC’s “v-safe” program, a smartphone-based tool where recipients of the Covid-19 vaccine can go for health check-ins. The tool allows people to go on their smartphone and provide information on how they’re feeling post-shot. The newly released data is eye-opening. According to the official CDC data shared by Siri, about 1.2 million people were unable to perform regular activities, 1.3 million had to miss work or school, and another 800,000 people required medical care after getting the vaccine. A total of 3,353,110 recipients were negatively impacted by the jab.

Siri appeared on Fox to talk about the lengthy process of attaining the documents. It took 463 days to receive the data, and Siri believes the CDC could have provided the information in a matter of minutes. “Why did it take numerous legal demands, multiple appeals – two lawsuits in fact – before the CDC finally handed over the v-safe data?” Siri asks.

These findings are very concerning; for years, the vaccine was advertised as “safe” and “effective.” Siri said, “A big reason that they pushed the Covid vaccine is [because] they said, ‘look, not everybody is gonna get – you know – seriously injured by Covid, but for many, it’ll prevent them from having symptoms, being hospitalized, missing work.’ Well, now that we have the data, we could see that getting the vaccine caused 25% of people who got the shot – within this data set of 10 million people – to miss work, to have some serious event affecting their normal life functions.

So far, 68.4% of the U.S. population has been fully vaccinated (as stated by Our World in Data). It’s difficult to determine just how many people have been negatively affected by the vaccine since the information on it seems to be suppressed. The CDC has not yet addressed the released documents, and the information is not available on their website. 

FDA restricts J&J’s COVID-19 vaccine due to blood clot risk

Authrsors: Associated Press

WASHINGTON (AP) — U.S. regulators on Thursday strictly limited who can receive Johnson & Johnson’s COVID-19 vaccine due to the ongoing risk of rare but serious blood clots.

The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J’s vaccine. U.S. authorities for months have recommended that Americans starting their COVID-19 vaccinations use the Pfizer or Moderna shots instead.

FDA officials said in a statement that they decided to restrict J&J’s vaccine after taking another look at data on the risk of life-threatening blood clots within two weeks of vaccination.

J&J’s vaccine was initially considered an important tool in fighting the pandemic because it required only one shot. But the single-dose option proved less effective than two doses of the Pfizer and Moderna vaccines.

Under the new FDA instructions, J&J’s vaccine could still be given to people who had a severe allergic reaction to one of the other vaccines and can’t receive an additional dose. J&J’s shot could also be an option for people who refuse to receive the mRNA vaccines from Pfizer and Moderna, and therefore would otherwise remain unvaccinated, the agency said.

A J&J spokesman said in an emailed statement: “Data continue to support a favorable benefit-risk profile for the Johnson & Johnson COVID-19 vaccine in adults, when compared with no vaccine.”

Despite the restriction, FDA’s vaccine chief Dr. Peter Marks said J&J’s vaccine “still has a role in the current pandemic response in the United States and across the global community.”

The FDA based its decision on “our safety surveillance systems and our commitment to ensuring that science and data guide our decisions

Nearly 15 million deaths associated with COVID-19, WHO says

The clotting problems first came up last spring, with the J&J shot in the U.S. and with a similar vaccine made by AstraZeneca that is used in other countries. At that time, U.S. regulators decided the benefits of J&J’s one-and-done vaccine outweighed what was considered a very rare risk — as long as recipients were warned.

COVID-19 causes deadly blood clots, too. But the vaccine-linked kind is different, believed to form because of a rogue immune reaction to the J&J and AstraZeneca vaccines because of how they’re made. It forms in unusual places, such as veins that drain blood from the brain, and in patients who also develop abnormally low levels of the platelets that form clots. Symptoms of the unusual clots include severe headaches a week or two after the J&J vaccination — not right away — as well as abdominal pain and nausea.

The New Brunswick, New Jersey-based company announced last month that it didn’t expect a profit from the vaccine this year and was suspending sales projections.

The rollout of the company’s vaccine was hurt by a series of troubles, including manufacturing problems at a Baltimore factory that forced J&J to import millions of doses from overseas.

Additionally, regulators added warnings about the blood clots and a rare neurological reaction called Guillain-Barré syndrome.

Pfizer and Moderna have provided the vast majority of COVID-19 vaccines in the U.S. More than 200 million Americans have been fully vaccinated with the companies’ two-dose shots while less than 17 million Americans got the J&J shot.